Study Evaluating Safety and Efficacy of UCART123 in | Clinical Research Studies Listing

$Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)$

Recruiting

18 years - 65 years

All

Phase 1

10 participants needed

1 Location

Brief description of study

This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Acute Myeloid Leukemia,Leukemia
Age: 18 years - 65 years
Gender: All

Male and Female, Age 18 - 65, Patients with relapsed or primary refractory Acute Myeloid Leukemia

Updated on 04 Aug 2024. Study ID: 844364

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)

Brief description of study

Eligibility of study

Find a site

Interested in the study